https://www.selleckchem.com/products/lee011.html
Uniquely, this trial randomizes participants in a larger population than the study population, given the impossibility of consenting and randomizing participants during emergencies. The primary endpoint is the change in pain scores in the ED from time of placement in treatment area to time of disposition (hospitalization, discharged home, or assigned to observation status) or a maximum treatment duration of 6hours. Additional outcomes include hospitalizations and ED visits seven days post enrollment, side effects, and safety assessments.